Elzonris for Blastic Plasmacytoid Dendritic Cell Neoplasm
ELZONRIS (tagraxofusp-erzs, Stemline® Therapeutics)
Indications: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older
Dosage: Intravenously at 2mcg/kg over 15 mins once daily on days 1 & 5 of a 21-day cycle
- First cycle recommended in inpatient setting, subsequent cycles either inpatient or other appropriate outpatient setting
Contraindications: None
Related Content
